TI

Kaspersky finds threat intelligence is the most sought-after security service for MSPs

Thursday, October 21, 2021 - 4:17pm

It presented the biggest opportunities for growth in 2021 in addition to remote workforce setup, with 65% of MSPs reporting security service revenue growth as a result.

Key Points: 
  • It presented the biggest opportunities for growth in 2021 in addition to remote workforce setup, with 65% of MSPs reporting security service revenue growth as a result.
  • According to Gartner , threat intelligence is a key aspect of security architecture that helps security and risk management technical professionals detect, triage, and investigate threats.
  • Among various threat intelligence services, the most interesting choices for MSPs is APT reporting (30%), threat campaigns and techniques of APT actors.
  • Today, when a reactive approach to cybersecurity is not enough, MSPs have to seriously address the choice of threat intelligence (TI) service providers.

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting

Thursday, October 21, 2021 - 12:00pm

BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage gene therapy program for mucopolysaccharidosis type II (MPS II, or Hunter syndrome), clinical-stage gene editing program for phenylketonuria (PKU), GTx-mAb program for paroxysmal nocturnal hemoglobinuria (PNH) and assays to evaluate levels of pre-existing antibodies to the Company’s adeno-associated viral vectors (AAVHSCs) during the 2021 European Society for Gene & Cell Therapy Virtual Conference (ESGCT).

Key Points: 
  • gene therapy candidate for MPS II, and showcased gene editing data in the PKU and humanized murine models, including on- and off-target assessment confirming the precision of our nuclease-free in vivo gene editing.
  • Encouraging data from our GTx-mAb platform showed a single dose resulted in sustained and robust expression of full-length antibodies from the liver consistent with anti-C5 therapeutics.
  • Further, we presented details of the methods of our neutralizing antibody assays used in our clinical trial screening.
  • Both methods are used in the screening phase of Homologys HMI-102 gene therapy pheNIX clinical trial to determine patient eligibility based on pre-existing Nabs.

Philips Projection Sets to Redefine Our Viewing Experience with the Launch of Two New Portable Projectors

Wednesday, October 20, 2021 - 3:30pm

With GoPix, Philips is launching a brand-new product line entirely dedicated to delivering users the perfect smartphone companion, while the new PicoPix member Philips PicoPix MaxTV is an all-in-one portable standalone unit.

Key Points: 
  • With GoPix, Philips is launching a brand-new product line entirely dedicated to delivering users the perfect smartphone companion, while the new PicoPix member Philips PicoPix MaxTV is an all-in-one portable standalone unit.
  • That's why we're thrilled to announce the PicoPix MaxTV, the state-of-the-art product in portable entertainment, and the GoPix 1, the leading-edge smartphone companion.
  • Both products offer the best viewing experiences and high-end features for ultimate convenience, within two distinct portable projector product lines."
  • Staying true to PicoPix's motto of "Streaming everywhere, gaming anywhere", the PicoPix MaxTV takes the portable experience to a whole new level.

Philips Projection Sets to Redefine Our Viewing Experience with the Launch of Two New Portable Projectors

Wednesday, October 20, 2021 - 3:30pm

With GoPix, Philips is launching a brand-new product line entirely dedicated to delivering users the perfect smartphone companion, while the new PicoPix member Philips PicoPix MaxTV is an all-in-one portable standalone unit.

Key Points: 
  • With GoPix, Philips is launching a brand-new product line entirely dedicated to delivering users the perfect smartphone companion, while the new PicoPix member Philips PicoPix MaxTV is an all-in-one portable standalone unit.
  • That's why we're thrilled to announce the PicoPix MaxTV, the state-of-the-art product in portable entertainment, and the GoPix 1, the leading-edge smartphone companion.
  • Both products offer the best viewing experiences and high-end features for ultimate convenience, within two distinct portable projector product lines."
  • Staying true to PicoPix's motto of "Streaming everywhere, gaming anywhere", the PicoPix MaxTV takes the portable experience to a whole new level.

Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

Thursday, October 14, 2021 - 1:23pm

BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai:603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.

Key Points: 
  • BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai:603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.
  • The two studies were conducted separately in subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567).
  • Gan & Lee Pharmaceuticalshasdeveloped the first Chinese domestic biosynthetic human insulin.
  • In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment.

Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

Thursday, October 14, 2021 - 1:15pm

BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai:603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.

Key Points: 
  • BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai:603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.
  • The two studies were conducted separately in subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567).
  • Gan & Lee Pharmaceuticalshasdeveloped the first Chinese domestic biosynthetic human insulin.
  • In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment.

Industry's most accurate 3D Hall-effect position sensor provides speed and precision for faster real-time control

Tuesday, October 12, 2021 - 2:00pm

DALLAS, Oct. 12, 2021 /PRNewswire/ --Texas Instruments (TI) (Nasdaq: TXN) today introduced the industry's most accurate 3D Hall-effect position sensor.

Key Points: 
  • DALLAS, Oct. 12, 2021 /PRNewswire/ --Texas Instruments (TI) (Nasdaq: TXN) today introduced the industry's most accurate 3D Hall-effect position sensor.
  • With the TMAG5170, engineers can achieve uncalibrated ultra-high precision at speeds up to 20 kSPS for faster and more accurate real-time control in factory automation and motor-drive applications.
  • The TMAG5170 is the industry's first 3D Hall-effect position sensor to provide a low 2.6% full-scale total error at room temperature.
  • To achieve faster, more accurate real-time control, the sensor supports measurements as high as 20 kSPS for low-latency throughput of high-speed mechanical motion.

TI Partners Advises Everywhere Wireless on Significant Growth Capital Investment from M/C Partners

Thursday, October 7, 2021 - 5:00pm

CHICAGO, Oct. 7, 2021 /PRNewswire-PRWeb/ --TI Partners, a New York- and Atlanta-based advisory and investment firm, announced that its client, Everywhere Wireless, LLC ("Everywhere Wireless"), has received a growth investment from M/C Partners ("M/C"), a Boston-based private equity firm focused on small and mid-sized businesses in the communications and technology services sectors.

Key Points: 
  • CHICAGO, Oct. 7, 2021 /PRNewswire-PRWeb/ --TI Partners, a New York- and Atlanta-based advisory and investment firm, announced that its client, Everywhere Wireless, LLC ("Everywhere Wireless"), has received a growth investment from M/C Partners ("M/C"), a Boston-based private equity firm focused on small and mid-sized businesses in the communications and technology services sectors.
  • Keegan Bonebrake, Founder and CEO of Everywhere Wireless, said, "Having reviewed a number of advisory proposals, we eventually engaged TI Partners due to their specialized industry knowledge.
  • TI Partners is highly focused on "Technology as Infrastructure", across both software and broader connectivity.
  • TI Partners is a full service financial advisory firm with offices in New York, Atlanta, and Los Angeles whose capabilities include buy-side, sell-side, equity and debt capital raises, as well as strategic advisory services.

NeuroBlade raises $83 Million in Series B Funding to Massively Accelerate Data Analytics

Wednesday, October 6, 2021 - 11:00am

NeuroBlade , the next generation of data acceleration solutions, announced today that it has secured $83 million in Series B funding, bringing total invested capital to $110 million.

Key Points: 
  • NeuroBlade , the next generation of data acceleration solutions, announced today that it has secured $83 million in Series B funding, bringing total invested capital to $110 million.
  • NeuroBlade has developed a new data analytics architecture that eliminates major data movement bottlenecks by integrating the data processing function inside memory, better known as processing-in-memory (PIM).
  • NeuroBlade accelerates data analytics and unclogs traditional bottlenecks by integrating its technology into a full system-level easy-to-deploy appliance.
  • NeuroBlade recognized that current architectures cannot scale to meet future data analytics needs, which led them to build a computational architecture that eliminates the data movement requirements and massively speeds data analytics performance.

Texas Instruments to webcast Q3 2021 earnings conference call

Tuesday, October 5, 2021 - 7:59pm

DALLAS, Oct. 5, 2021 /PRNewswire/ --Texas Instruments Incorporated (TI) (Nasdaq: TXN) will webcast its third quarter 2021 earnings conference call on Tuesday, Oct. 26, at 3:30 p.m. Central time.

Key Points: 
  • DALLAS, Oct. 5, 2021 /PRNewswire/ --Texas Instruments Incorporated (TI) (Nasdaq: TXN) will webcast its third quarter 2021 earnings conference call on Tuesday, Oct. 26, at 3:30 p.m. Central time.
  • You may access the audio webcast on the Investor Relations section of the company's website at www.ti.com/ir .
  • An archived copy of the webcast will be available shortly after the call concludes.
  • Texas Instruments Incorporated(Nasdaq: TXN) is a global semiconductor company that designs, manufactures, tests and sells analog and embedded processing chips formarkets such as industrial, automotive, personal electronics, communications equipment and enterprise systems.